New Immunotherapy-Chemo combo aims to tackle rare sarcoma

NCT ID NCT07243626

Recruiting now Disease control Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether adding envafolimab (an immunotherapy) to standard chemotherapy (doxorubicin and ifosfamide) can improve outcomes for people with advanced soft tissue sarcoma who haven't had prior treatment. About 25 adults will receive the combination every 3 weeks. The study will measure how long the cancer stays under control and any side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: envafolimab (a PD-L1 inhibitor) combined with doxorubicin and ifosfamide (chemotherapy)
What this could lead to: If successful, this could offer a more effective first-line treatment option for advanced soft tissue sarcoma, potentially improving tumor shrinkage and delaying disease progression.
What could go wrong: This is a small, early-phase trial (25 participants) with no control group, so results may not be conclusive. The combination may cause significant side effects, and not all sarcoma subtypes may respond.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOFT TISSUE SARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

sarcoma soft tissue sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOFT TISSUE SARCOMA

Contacts and locations

Locations

Department of Medical Oncology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
RECRUITING

Hanzhong, Zhejiang, 310009, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.